Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.abbvie.com
Press Releases | AbbVie Newsroom
Get the latest updates from Press Releases | AbbVie Newsroom directly as they happen.
Follow now 238 followers
Latest posts
Last updated over 1 year ago
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
about 2 years ago
- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ®)...
AbbVie to Present at the Bank of America Securities Healthcare Conference
about 2 years ago
NORTH CHICAGO, Ill., May 2, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will...
AbbVie Reports First-Quarter 2023 Financial Results
about 2 years ago
NORTH CHICAGO, Ill., April 27, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial...
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting
about 2 years ago
NORTH CHICAGO, Ill., April 21, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today...
Allergan Aesthetics Celebrates the Journeys of Women Surgeons with LIMITLESS
about 2 years ago
IRVINE, Calif., April 18, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company...
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
about 2 years ago
NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
about 2 years ago
– Seventh approved indication for RINVOQ in the European Union (EU) and...
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year
about 2 years ago
NORTH CHICAGO, Ill., April 12, 2023 /PRNewswire/ -- AbbVie today announced that...
Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
about 2 years ago
NORTH CHICAGO, Ill., XX – AbbVie (NYSE: ABBV) announced today the intent...
AbbVie to Host First-Quarter 2023 Earnings Conference Call
about 2 years ago
NORTH CHICAGO, Ill., April 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will...
CoolSculpting® Elite Announces First Ever CoolMonth
about 2 years ago
IRVINE, Calif., April 3, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company...
Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
about 2 years ago
IRVINE, Calif., March 29, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE...